临床试验是否正确评估了c-Met抑制剂？
Have Clinical Trials Properly Assessed c-Met Inhibitors?
作者信息
Hughes Veronica S, Siemann Dietmar W
机构信息
Department of Radiation Oncology, University of Florida, 2033 Mowry Road, Cancer Genetic Research Complex, Room 485E, Gainesville, FL 32610, USA.
Department of Radiation Oncology, University of Florida, 2033 Mowry Road, Cancer Genetic Research Complex, Room 485E, Gainesville, FL 32610, USA.
出版信息
Trends Cancer. 2018 Feb;4(2):94-97. doi: 10.1016/j.trecan.2017.11.009.
Abstract
The c-Met/HGF pathway is implicated in cancer progression and dissemination. Many inhibitors have been developed to target this pathway. Unfortunately, most trials have failed to demonstrate efficacy. However, clinical trials have not adequately tested the concept of c-Met pathway inhibition due to the lack of appropriate patient selection criteria.
摘要
c-Met/HGF信号通路与癌症进展和扩散有关。已经开发了许多靶向该信号通路的抑制剂。不幸的是，大多数试验都未能证明其有效性。然而，由于缺乏合适的患者选择标准，临床试验尚未充分验证c-Met信号通路抑制的概念。
相似文献
1
Have Clinical Trials Properly Assessed c-Met Inhibitors?
Trends Cancer. 2018 Feb;4(2):94-97. doi: 10.1016/j.trecan.2017.11.009.
2
Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
Trends Mol Med. 2010 Jan;16(1):37-45. doi: 10.1016/j.molmed.2009.11.005. Epub 2009 Dec 22.
3
c-Met inhibition.
Clin Adv Hematol Oncol. 2006 Nov;4(11):823-4.
4
The emerging role of MET/HGF inhibitors in oncology.
Cancer Treat Rev. 2013 Nov;39(7):793-801. doi: 10.1016/j.ctrv.2013.02.001. Epub 2013 Feb 28.
5
Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
Oncogene. 2016 Oct 20;35(42):5457-5467. doi: 10.1038/onc.2016.36. Epub 2016 Mar 21.
6
Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
J Pathol. 2014 Jan;232(2):210-8. doi: 10.1002/path.4268.
7
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.
Hepatology. 2018 Mar;67(3):1132-1149. doi: 10.1002/hep.29496. Epub 2018 Feb 1.
8
c-MET kinase inhibitors: a patent review (2011 - 2013).
Expert Opin Ther Pat. 2014 Feb;24(2):217-30. doi: 10.1517/13543776.2014.864279. Epub 2013 Nov 25.
9
C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
J Cell Physiol. 2017 Oct;232(10):2657-2673. doi: 10.1002/jcp.25794. Epub 2017 Apr 10.
10
Trends in the development of MET inhibitors for hepatocellular carcinoma.
Future Oncol. 2016 May;12(10):1275-86. doi: 10.2217/fon.16.3. Epub 2016 Mar 17.
引用本文的文献
1
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.
Target Oncol. 2025 Jul 18. doi: 10.1007/s11523-025-01166-0.
2
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network.
Cancer Res Commun. 2024 Jul 1;4(7):1863-1880. doi: 10.1158/2767-9764.CRC-23-0370.
3
Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling.
Front Pharmacol. 2024 Jan 10;14:1340401. doi: 10.3389/fphar.2023.1340401. eCollection 2023.
4
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling.
Br J Cancer. 2024 Feb;130(3):380-393. doi: 10.1038/s41416-023-02495-5. Epub 2023 Dec 18.
5
Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors.
JTO Clin Res Rep. 2022 Dec 13;4(2):100449. doi: 10.1016/j.jtocrr.2022.100449. eCollection 2023 Feb.
6
Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation.
Cancer Sci. 2023 May;114(5):1958-1971. doi: 10.1111/cas.15733. Epub 2023 Feb 7.
7
A miniaturized screening platform to identify novel regulators of extracellular matrix alignment.
Cancer Res Commun. 2022 Nov;2(11):1471-1486. doi: 10.1158/2767-9764.CRC-22-0157. Epub 2022 Nov 22.
8
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis.
J Clin Med. 2022 Nov 26;11(23):6987. doi: 10.3390/jcm11236987.
9
An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies.
Cell Mol Life Sci. 2022 Dec 10;80(1):6. doi: 10.1007/s00018-022-04634-2.
10
The Occurrence of MET Ectodomain Shedding in Oral Cancer and Its Potential Impact on the Use of Targeted Therapies.
Cancers (Basel). 2022 Mar 15;14(6):1491. doi: 10.3390/cancers14061491.
本文引用的文献
1
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
Clin Cancer Res. 2016 Jul 15;22(14):3683-94. doi: 10.1158/1078-0432.CCR-15-2323. Epub 2016 Mar 21.
2
C-MET overexpression and amplification in gliomas.
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14932-8. eCollection 2015.
3
Retrospective Review of MET Gene Mutations.
Oncoscience. 2015 May 14;2(5):533-41. doi: 10.18632/oncoscience.161. eCollection 2015.
4
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.
5
Targeting MET in cancer: rationale and progress.
Nat Rev Cancer. 2012 Jan 24;12(2):89-103. doi: 10.1038/nrc3205.
6
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):570-5. doi: 10.1073/pnas.1119059109. Epub 2011 Dec 27.
7
c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
J Thorac Oncol. 2012 Feb;7(2):331-9. doi: 10.1097/JTO.0b013e318241655f.
8
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29.
9
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Lung Cancer. 2004 May;44(2):221-30. doi: 10.1016/j.lungcan.2003.12.014.
10
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
J Clin Oncol. 2003 Jun 15;21(12):2237-46. doi: 10.1200/JCO.2003.10.038. Epub 2003 May 14.
Zotero 插件